NGeneBio
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
NGeneBio develops diagnostic tools and software that analyse a person's genetic information to help identify diseases, using a technology called next-generation sequencing (NGS), which reads DNA rapidly and at scale.
Its products and services are used in medical and research settings, and it also supplies medical-grade software and databases. Listed on KOSDAQ, South Korea's tech-focused small-cap exchange, the company has been broadening its registered business scope to include healthcare product distribution, logistics services to hospitals and pharmacies, and medical-device e-commerce.
Summary is AI-generated and may contain errors · figures from DART filings
NGeneBio in five facts
What does NGeneBio do?
NGeneBio develops diagnostic tools and software that analyse a person's genetic information to help identify diseases, using a technology called next-generation sequencing (NGS), which reads DNA rapidly and at scale.
Where is NGeneBio listed and in which sector?
NGeneBio (Korean name: 엔젠바이오) trades under KRX code 354200 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is NGeneBio?
Its market capitalisation was US$10.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were NGeneBio's latest annual revenue and operating profit?
For fiscal year 2025, NGeneBio reported revenue of US$16M, an operating loss of US$6.2M and a net loss of US$5.1M, per its annual report on DART (data retrieved from DART on 2026-06-03). Revenue was up 273.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-03
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (abbreviated)Oct 8
- Other market noticeOct 7
- Other market noticeSep 22
- [Amended] Securities issuance results (voluntary)Sep 22
- [Amended] Securities issuance reportSep 22
- [Amended] Material event report (rights offering)
NGeneBio updated the terms of a new share issuance to raise US$5.69M, about 64.5% of its market value.
Capital raise · Sep 22 · 6 versions - Early redemption of convertible bonds (incl. overseas CBs)
ENGEN BIO acquired convertible bonds (4th series) before maturity on 2026-09-18 for US$1.82M (including principal and interest), with a face value of US$1.74M, through mutual agreement with bondholders for early redemption, with the bonds to be cancelled. The bonds were originally issued on 2024-06-14 with a maturity date of 2029-06-14 and a conversion price of US$3.88 per share.
Capital raise · Sep 18 - Securities issuance results (voluntary)Sep 17
- Report on large shareholdings (5% rule) (standard)Sep 17
- Securities issuance reportSep 17
- Subscription results of rights offering or equity-linked bonds (voluntary)Capital raise · Sep 16
- Change of CEOSep 15
- Subscription results of rights offering or equity-linked bonds (voluntary)Capital raise · Sep 11
- Rights offering: final issue price setCapital raise · Sep 7
- [Amended] ProspectusSep 7
- [Terms finalized] Securities registration statement (equity)Sep 7
- DisclosureSep 4
- Ex-rights (rights offering)
NGeneBio's shares will trade ex-rights from July 21, 2026 at a base price of US$0.95, in connection with its rights offering.
Capital raise · Jul 20 - Rights offering: round 1 issue price set
NGeneBio set the round 1 issue price for its planned rights offering of 7,150,000 common shares at US$0.73 per share as of July 16, 2026; the final issue price will be calculated on September 4, 2026 and disclosed September 7, 2026.
Capital raise · Jul 20 - Trading suspension (share consolidation/split registration)M&A · Jun 18
- Completion report on merger, etc. (merger)M&A · Mar 31
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
NGeneBio reported consolidated results for FY2025: revenue of US$14.8M (+273.2% year on year), an operating loss of US$5.78M and a net loss of US$4.52M.
Earnings · Feb 27 - Material event report (decision to sell own convertible bonds)Capital raise · Feb 3
- [Amended] Merger decision (subsidiary)M&A · Jan 30
- [Amended] Material event report (merger)M&A · Jan 30